Cytokine levels (IL-6 and INF-γ), acute phase response and nutritional status as prognostic factors in lung cancer

被引:184
作者
Martín, F [1 ]
Santolaria, F [1 ]
Batista, N [1 ]
Milena, A [1 ]
Gonzalez-Reimers, E [1 ]
Brito, MJ [1 ]
Oramas, J [1 ]
机构
[1] Univ La Laguna, Hosp Univ Canarias, Med Interna Serv, Secc Oncol Med, Tenerife, Spain
关键词
IFN-gamma; IL-6; lung cancer; malnutrition; survival;
D O I
10.1006/cyto.1998.0398
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Raised serum levels of interleukin 6 (IL-6) have been described in cancer patients. This cytokine mediates the acute phase response and has been also involved in the pathogenesis of cancer cachexia, The objectives of the present study were: (1) to determine the relationships of IL-6 and other cytokines with neoplasia extension, acute phase response and nutritional status, in lung cancer patients; and (2) to establish the prognostic value of serum cytokine levels. A prospective study in which IL-1, IL-2, IL-6, tumour necrosis factor alpha (TNF-alpha) and inteferon gamma (IFN-gamma) have been determined in 66 newly diagnosed lung cancer patients. Nutritional status was assessed objectively. Serum levels of growth hormone (GH), insulin growth factor 1 (IGF-1) and acute phase reactants as C Reactive Protein, alpha 1 antitrypsin and ferritine, were determined. Increased IL-6 levels were related to extensive disease, impaired performance status, enhanced acute phase response and malnutrition. Raised serum IL-6 levels, extensive disease, low Karnofsky index, malnutrition, acute phase response and low IFN-gamma were all related to a shorter survival. When assessed by a multivariate analysis, IL-6 kept its independent prognostic value together with age, disease extension, and decreased IFN-gamma serum levels. IL-6 is increased in lung cancer patients, enhances the acute phase response in them, and is correlated with poor nutritional status, impaired performance status and shorter survival. (C) 1999 Academic Press.
引用
收藏
页码:80 / 86
页数:7
相关论文
共 37 条
  • [1] [Anonymous], JPEN J PARENTER ENTE, DOI DOI 10.1177/01860717700100101
  • [2] SERUM LEVELS OF INTERLEUKIN-6, A POTENT MYELOMA CELL-GROWTH FACTOR, AS A REFLECT OF DISEASE SEVERITY IN PLASMA-CELL DYSCRASIAS
    BATAILLE, R
    JOURDAN, M
    ZHANG, XG
    KLEIN, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (06) : 2008 - 2011
  • [3] SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER
    BEREK, JS
    CHUNG, C
    KALDI, K
    WATSON, JM
    KNOX, RM
    MARTINEZMAZA, O
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (04) : 1038 - 1043
  • [4] BLAY JY, 1992, CANCER RES, V52, P3317
  • [5] DALY JM, 1996, NUTR METABOLISM SURG, P601
  • [6] PROGNOSTIC EFFECT OF WEIGHT-LOSS PRIOR TO CHEMOTHERAPY IN CANCER-PATIENTS
    DEWYS, WD
    BEGG, C
    LAVIN, PT
    BAND, PR
    BENNETT, JM
    BERTINO, JR
    COHEN, MH
    DOUGLASS, HO
    ENGSTROM, PF
    EZDINLI, EZ
    HORTON, J
    JOHNSON, GJ
    MOERTEL, CG
    OKEN, MM
    PERLIA, C
    ROSENBAUM, C
    SILVERSTEIN, MN
    SKEEL, RT
    [J]. AMERICAN JOURNAL OF MEDICINE, 1980, 69 (04) : 491 - 497
  • [7] TUMOR-NECROSIS-FACTOR-ALPHA, INTERLEUKIN-1-BETA AND INTERLEUKIN-6 IN PATIENTS WITH RENAL CELL-CARCINOMA
    DOSQUET, C
    SCHAETZ, A
    FAUCHER, C
    LEPAGE, E
    WAUTIER, JL
    RICHARD, F
    CABANE, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1994, 30A (02) : 162 - 167
  • [8] CYTOKINES, THE ACUTE-PHASE RESPONSE, AND RESTING ENERGY-EXPENDITURE IN CACHECTIC PATIENTS WITH PANCREATIC-CANCER
    FALCONER, JS
    FEARON, KCH
    PLESTER, CE
    ROSS, JA
    CARTER, DC
    [J]. ANNALS OF SURGERY, 1994, 219 (04) : 325 - 331
  • [9] FREDRIX EWHM, 1991, CANCER, V68, P1616, DOI 10.1002/1097-0142(19911001)68:7<1616::AID-CNCR2820680725>3.0.CO
  • [10] 2-3